Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan T Ciccarelli

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Leukemia Research|December 3, 2014
Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion proteinTinghui Hu, Bryan T Ciccarelli
Haematologica|September 1, 2025
A CHIP off the old (MDS) blockSelina M Luger, Bryan T Ciccarelli
Small Gtpases|December 9, 2014
Regulation of vesicle transport and cell motility by Golgi-localized DbsEthan R Fitzpatrick, Tinghui Hu, Bryan T Ciccarelli, et al.
Leukemia Research|September 6, 2020
Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CMLBryan T Ciccarelli, Tinghui Hu, Qing Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2013
Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administrationSteven P Treon, Christina K Tripsas, Bryan T Ciccarelli, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27Yangsheng Zhou, Xia Liu, Lian Xu, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemiaBryan T Ciccarelli, Guang Yang, Evdoxia Hatjiharissi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogsXavier Leleu, Jacob Soumerai, Aldo Roccaro, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemiaBryan T Ciccarelli, Christopher J Patterson, Zachary R Hunter, et al.
Blood|May 4, 2007
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphismEvdoxia Hatjiharissi, Lian Xu, Daniel Ditzel Santos, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Leukemia Research|December 3, 2014
Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion proteinTinghui Hu, Bryan T Ciccarelli
Haematologica|September 1, 2025
A CHIP off the old (MDS) blockSelina M Luger, Bryan T Ciccarelli
Small Gtpases|December 9, 2014
Regulation of vesicle transport and cell motility by Golgi-localized DbsEthan R Fitzpatrick, Tinghui Hu, Bryan T Ciccarelli, et al.
Leukemia Research|September 6, 2020
Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CMLBryan T Ciccarelli, Tinghui Hu, Qing Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2013
Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administrationSteven P Treon, Christina K Tripsas, Bryan T Ciccarelli, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27Yangsheng Zhou, Xia Liu, Lian Xu, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemiaBryan T Ciccarelli, Guang Yang, Evdoxia Hatjiharissi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogsXavier Leleu, Jacob Soumerai, Aldo Roccaro, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemiaBryan T Ciccarelli, Christopher J Patterson, Zachary R Hunter, et al.
Blood|May 4, 2007
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphismEvdoxia Hatjiharissi, Lian Xu, Daniel Ditzel Santos, et al.
Pageof 2